Takero Shindo

Takero Shindo

Auto-generated profile, based on publicly available information

Takero Shindo

Department of Hematology/Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Nature
Verified
Journal Article
Open access
PDF file
NSNobukatsu Sawamoto
Nobukatsu Sawamoto
DDDaisuke Doi
Daisuke Doi
ENEtsuro Nakanishi
Etsuro Nakanishi
MSMasanori Sawamura
Masanori Sawamura
TKTakayuki Kikuchi
Takayuki Kikuchi
JTJun Takahashi
Jun Takahashi
Parkinson’s disease is caused by the loss of dopamine neurons, causing motor symptoms. Initial cell therapies using fetal tissues showed promise but had complications and ethical concerns1,2,3,4,5. Pluripotent stem (PS) cells emerged as a promising alternative for developing safe and effective treatments6. In this phase I/II trial at Kyoto University Hospital, seven patients (ages 50–69) received bilateral transplantation of dopaminergic progenitors derived from induced PS (iPS) cells. Primary outcomes focused on safety and adverse events, while secondary outcomes assessed motor symptom changes and dopamine production for 24 months. There were no serious adverse events, with 73 mild to moderate events. Patients’ anti-parkinsonian medication doses were maintained unless therapeutic adjustments were required, resulting in increased dyskinesia. Magnetic resonance imaging showed no graft overgrowth. Among six patients subjected to efficacy evaluation, four showed improvements in the Movement Disorder Society Unified Parkinson’s Disease Rating Scale part III OFF score, and five showed improvements in the ON scores. The average changes of all six patients were 9.5 (20.4%) and 4.3 points (35.7%) for the OFF and ON scores, respectively. Hoehn–Yahr stages improved in four patients. Fluorine-18-l-dihydroxyphenylalanine (18F-DOPA) influx rate constant (Ki) values in the putamen increased by 44.7%, with higher increases in the high-dose group. Other measures showed minimal changes. This trial (jRCT2090220384) demonstrated that allogeneic iPS-cell-derived dopaminergic progenitors survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinson’s disease.

31 May 2018 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
HUHiroshi Ureshino
Hiroshi Ureshino
TSTakero Shindo
Takero Shindo
HKHiroto Kojima
Hiroto Kojima
YKYasushi Kusunoki
Yasushi Kusunoki
YMYuki Miyazaki
Yuki Miyazaki
SKShinya Kimura
Shinya Kimura
Response to tyrosine kinase inhibitors (TKIs) is variable in chronic myeloid leukemia (CML), and elevated natural killer (NK) cells during TKI therapy are positively correlated with superior outcomes. NK cell function involves interactions of their killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I on target cells, and the avidity of KIR–HLA interactions depends on the combination of KIR and HLA alleles. We hypothesized that KIR and HLA polymorphisms may influence response to TKIs. KIR and HLA allele genotyping was performed by next-generation sequencing for 76 CML cases, and association with clinical outcome was analyzed. Second-generation TKIs as first-line therapy and patients' sex (female) were strongly associated with achievement of complete molecular response (CMR: MR4.0) after 2 years (P < 0.001 and P = 0.002, respectively). After adjustment for these two characteristics, several KIR alleles remained associated with achievement of MR4.0: KIR2DL4*005/011 or *008 (HR = 1.797, P = 0.032); KIR2DS4*003 or *007/010 (HR = 3.348, P < 0.001); KIR3DL1*005 (HR = 2.746, P = 0.003); and KIR3DL2*009 or *010 [HR = 1.980 (1.109–3.524), P = 0.021]. Strong linkage among these alleles exists, implying that they comprise favorable KIR allele haplotypes. Allelic polymorphisms of KIR3DL1 and HLA-B determine their differential avidity into strong/weak or no interaction. Patients carrying noninteracting KIR3DL1 and HLA-B allele pairs achieved better outcomes than those with strongly interacting pairs, and KIR3DL1*005 associated with a positive outcome among patients with weak-interacting pairs. Thus, KIR3DL1*005 and its associated haplotypes associated with superior TKI therapeutic effects. The combinations of these KIR and HLA alleles may correlate with potent NK cell immunity against CML. Cancer Immunol Res; 6(6); 745–54. ©2018 AACR.

14 July 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
HMHiroyuki Muranushi
Hiroyuki Muranushi
TSTakero Shindo
Takero Shindo
MHMasakatsu Hishizawa
Masakatsu Hishizawa
MTMasahito Tokunaga
Masahito Tokunaga
AWAtsushi Wake
Atsushi Wake
MMMari Morita-Fujita
Mari Morita-Fujita

1 September 2019 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
ATAkihiro Takahagi
Akihiro Takahagi
TSTakero Shindo
Takero Shindo
TCToyofumi F. Chen-Yoshikawa
Toyofumi F. Chen-Yoshikawa
AYAkihiko Yoshizawa
Akihiko Yoshizawa
FGFumiaki Gochi
Fumiaki Gochi
HDHiroshi Date
Hiroshi Date
Delayed immunological rejection after human lung transplantation causes chronic lung allograft dysfunction, which is associated with high mortality. Delayed rejection may be attributable to indirect alloantigen presentation by host antigen-presenting cells; however, its pathophysiology is not fully understood. The mitogen-activated protein kinase pathway is activated in T cells upon stimulation, and we previously showed that the MEK inhibitor, trametinib, suppresses graft-versus-host disease after murine bone marrow transplantation. We investigated whether trametinib suppresses graft rejection after two types of rat lung transplantation and analyzed its immunological mode of action. Major histocompatibility complex–mismatched transplantation from brown Norway rats into Lewis rats and minor histocompatibility antigen–mismatched transplantation from Fischer 344 rats into Lewis rats were performed. Cyclosporine (CsA) and/or trametinib were administered alone or consecutively. Acute and delayed rejection, lymphocyte infiltration, and pulmonary function were evaluated. Administration of trametinib after CsA suppressed delayed rejection, reduced inflammatory cell infiltration and fibrosis within the graft, and preserved pulmonary functions at Day 28. Trametinib suppressed functional differentiation of T and B cells in the periphery but preserved thymic T cell differentiation. Donor B cells within the graft disappeared by Day 14, indicating that delayed graft rejection at Day 28 was mainly due to indirect presentation by host antigen-presenting cells. Finally, trametinib administration without CsA preconditioning suppressed rejection after minor histocompatibility antigen–mismatched transplantation. Trametinib attenuates delayed rejection upon major histocompatibility complex–mismatched transplantation by suppressing indirect presentation and is a promising candidate to treat chronic lung allograft dysfunction in humans.

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
PDF file
TATakashi Akutagawa
Takashi Akutagawa
TSTakero Shindo
Takero Shindo
KYKohei Yamanouchi
Kohei Yamanouchi
MHMasaki Hayakawa
Masaki Hayakawa
HUHiroshi Ureshino
Hiroshi Ureshino
KFKazuma Fujimoto
Kazuma Fujimoto
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

3 October 2017 in Hematological Oncology
Verified
Journal Article
Open access
PDF file
HUHiroshi Ureshino
Hiroshi Ureshino
TAToshihiko Ando
Toshihiko Ando
HKHaruna Kizuka
Haruna Kizuka
KKKana Kusaba
Kana Kusaba
HSHaruhiko Sano
Haruhiko Sano
SKShinya Kimura
Shinya Kimura
It has been well documented that patients may develop cytokine‐release syndrome (CRS) following the administration of monoclonal antibodies, such as chimeric antigen receptor‐modified T cell. Cytokine‐release syndrome is a common complication in patients who have received haploidentical donor allogeneic haematopoietic cell transplantation (haplo‐HCT). Although severe CRS after haplo‐HCT is a potentially life‐threatening toxicity, a standard treatment has not been established. Cytokine blockade with tocilizumab, an anti‐IL‐6 receptor antibody, has been effective for the treatment of patients with CRS after chimeric antigen receptor‐modified T‐cell treatment and has also improved CRS after haplo‐HCT. A 46‐year‐old man was diagnosed with haemophagocytic syndrome associated with Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma. Salvage chemotherapy was unsuccessful; consequently, he received haplo‐HCT. On day +4, he developed grade 3 CRS, subsequently high‐dose corticosteroid initiated. Nevertheless, on day +6, he developed grade 4 CRS, resulting in requirement for ventilator support and multiple vasopressors. Corticosteroid could not improve severe CRS; therefore, tocilizumab was administered on day +14. Serum C‐reactive protein level transiently decreased and weaned multiple vasopressors. Although CRS improved, he developed candidaemia; consequently, he died on day +34. Tocilizumab could transiently improve severe CRS after haplo‐HCT. Although tocilizumab may have led to the improvement of CRS, a remaining concern is whether it inhibited the patient's ability to mount antifungal immunity, leading to their demise.